ESR1 and breast cancer: Ryu et al. [49] reported the following: (1) BC patients positive for ER in the PT (ER(+)) and BC patients positive for HER2 in the PT (HER2(+)) have a much longer TVDT than BC patients with triple-negative expression in the PT (p < 0.05).